Galectins and Ovarian Cancer

by Chisa Shimada, Rui Xu, Linah Al-Alem, Marina Stasenko, David R. Spriggs, Bo R. Rueda
Published 2020-05-01

The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells

by Chiara Bellio, Celeste DiGloria, David R. Spriggs, Rosemary Foster, Whitfield B. Growdon, Bo R. Rueda
Published 2019-10-01

Time to publication of oncology trials and why some trials are never published.

by Paul B Chapman, Nathan J Liu, Qin Zhou, Alexia Iasonos, Sara Hanley, George J Bosl, David R Spriggs
Published 2017-01-01

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies

by Marina Stasenko, Evan Smith, Oladapo Yeku, Kay J. Park, Ian Laster, Kwangkook Lee, Sven Walderich, Elizabeth Spriggs, Bo Rueda, Britta Weigelt, Dmitriy Zamarin, Thapi Dharma Rao, David R. Spriggs
Published 2021-02-01

Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.

by Thapi D Rao, Huasong Tian, Xun Ma, Xiujun Yan, Sahityasri Thapi, Nikolaus Schultz, Nestor Rosales, Sebastien Monette, Amy Wang, David M Hyman, Douglas A Levine, David Solit, David R Spriggs
Published 2015-01-01

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

by Roisin E. O’Cearbhaill, Govind Ragupathi, Jianglong Zhu, Qian Wan, Svetlana Mironov, Guangbin Yang, Maria K. Spassova, Alexia Iasonos, Sara Kravetz, Ouathek Ouerfelli, David R. Spriggs, Samuel J. Danishefsky, Paul J. Sabbatini
Published 2016-04-01